Helixgate

Helixgate

Uncategorized

Antigen‑Stabilized Nanobody Probes Enable On‑Demand, Multicolor Protein Imaging

Published

on

Fluorescent probes have reshaped how biologists study living systems, making it possible to watch viruses invade cells, follow the cell’s internal waste‑disposal machinery, and track the signaling events that fuel tumor growth. Yet even with decades of innovation, a fundamental limitation has persisted: most fluorescent nanobody probes glow whether or not they are bound to their targets. That constant background haze can blur the very molecular details researchers are trying to resolve.

A new imaging platform developed by scientists at Albert Einstein College of Medicine and the Salk Institute for Biological Studies aims to eliminate that problem entirely. The technology, described in Nature Methods in a paper titled “Synthetic multicolor antigen-stabilizable nanobody platform for intersectional labelling and functional imaging,” uses engineered fluorescent nanobodies that become brightly fluorescent only when they bind their intended protein targets. These “on‑demand” probes, known as VIS‑Fbs (visible-spectrum target-stabilizable fluorescent nanobodies), illuminate proteins inside living cells and animals with far greater clarity than conventional tools.

“The key advantage of our approach is that the signal appears only where the target protein is present,” said Vladislav Verkhusha, PhD, co‑corresponding author and professor of genetics at Einstein. “That eliminates the background glow that has long limited the precision of intracellular imaging.” His collaborator, Axel Nimmerjahn, PhD, professor and the Françoise Gilot‑Salk Chair at Salk, added, “This work establishes a versatile platform for imaging proteins with high specificity and minimal background. It opens new opportunities to study how molecular and cellular processes unfold in real time across diverse biological systems.”

Nanobodies have become increasingly valuable for live‑cell imaging because they can be engineered to bind specific proteins with high affinity. But their ongoing fluorescence has remained a stubborn obstacle. The VIS‑Fb design solves this by making the probes unstable when unbound; they rapidly degrade unless they encounter their target. Binding stabilizes the nanobody and triggers bright fluorescence, reducing background noise by as much as 100‑fold. The team also created VIS‑Fbs that span nearly the entire visible spectrum, from blue to far red, enabling simultaneous tracking of multiple proteins or cellular processes within the same cell.

The researchers developed a modular engineering platform, instead of a single probe, capable of generating VIS‑Fbs for a wide range of targets and experimental needs. They integrated more than 20 fluorescent proteins and biosensors into multiple nanobody scaffolds, creating a flexible system that supports multicolor imaging, light‑switchable variants for precise temporal control, and functional readouts of ions and metabolites. This allows the probes not only to show where proteins are but also to show what those proteins are doing in real time. According to first author Natalia Barykina, PhD, “The VIS‑Fb approach allows us to identify and track specific cell populations in living organisms based on the proteins they express, rather than just their location.”

In mice, VIS‑Fbs allowed for high‑contrast imaging of neuronal and astrocyte activity during behavior. In zebrafish embryos, the probes captured rapid developmental changes and responses to drugs that modulate signaling pathways. “Our results show that this imaging platform offers a much clearer and more precise view of how proteins behave inside living systems,” Verkhusha said. “It opens the door to studying complex biological processes, such as cell signaling, development, and disease progression, in new ways.”

The post Antigen‑Stabilized Nanobody Probes Enable On‑Demand, Multicolor Protein Imaging appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision

Published

on

The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the asset given the unmet need and overall data.

Continue Reading

Uncategorized

Lilly exits Rigel alliance, adding to RIPK1 scrap heap

Published

on

Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous system indications.

Continue Reading

Uncategorized

Lilly, Novo dip as proposed Medicare coverage for GLP-1 pilot thrown off balance

Published

on

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that would have made GLP-1 drugs more affordable to patients.

Continue Reading
Advertisement

Trending